Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertensionBiochemical and imaging profiles in 271...
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Media Release COPENHAGEN, Denmark; October 28, 2022 Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration...
TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA),...
BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical...
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s...
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data...
PRESS RELEASE VacV Biotherapeutics emerges from stealth mode to bring ground-breaking cancer immunotherapies to the clinic Enhanced systemic delivery system...
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ETCompany to host “The Road Taken” R&D Event in Boston...
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing...
Conference to focus upon improving patient experience for difficult-to-treat cancerFLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology...
- Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 - - Two clinical posters highlighting...
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive...
SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune...
Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study...